文献速递甲状腺疾病

美国低风险分化型甲状腺癌幸存者的全因与病因特异性死亡率

All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States.
PubMed 文献 · Thyroid · 2024-01-22

基于美国SEER-12数据库1992-2019年51,854例低风险分化型甲状腺癌患者,随访中位8.8年,甲状腺癌仅占死亡4.3%;全因(除甲状腺癌外)死亡率低于匹配一般人群(SMR=0.69),但胰腺癌、肾及肾盂癌、骨髓瘤和白血病死亡率升高,且诊断后≥10年关联更强;放射性碘治疗与病因特异性死亡风险无关。

要点

  • 低风险分化型甲状腺癌患者总体死亡率和病因特异性死亡率较低。
  • 甲状腺癌仅占全部死亡的4.3%,最常见死因为其他恶性肿瘤和心血管疾病。
  • 胰腺癌、肾及肾盂癌、骨髓瘤和白血病死亡率升高,诊断后≥10年关联更强。

核心结论

  • 低风险分化型甲状腺癌患者总体及病因特异性死亡率较低,结果令人安心。
  • 某些后续癌症死亡率升高,需进一步研究确认和理解。

研究设计与样本

  • 基于美国监测、流行病学和最终结果(SEER)-12癌症登记数据库(1992-2019年)的队列研究。
  • 纳入51,854例首次原发低风险分化型甲状腺癌患者(≤4 cm、局限期),81.8%为女性。
  • 采用竞争风险估计病因特异性累积死亡率,计算标准化死亡比(SMR)及置信区间(CI),并用Cox比例风险模型分析放射性碘治疗与病因特异性死亡的关联。

主要发现

  • 随访中位8.8年(范围0-28年),记录3467例(6.7%)死亡;甲状腺癌仅占4.3%(n=148)。
  • 最常见死因为其他恶性肿瘤(n=1031,29.7%)和心血管疾病(n=912,26.3%)。
  • 甲状腺癌、其他恶性肿瘤(除甲状腺癌或非黑色素瘤皮肤癌)和心血管疾病的20年累积死亡率分别为0.6%、4.6%和3.9%。
  • 全因(除甲状腺癌外)死亡率低于匹配的一般人群(SMR=0.69 [CI 0.67-0.71]),所有恶性肿瘤合计(除甲状腺癌外;SMR=0.80 [CI 0.75-0.85])和心血管疾病(SMR=0.64 [CI 0.60-0.69])也低于预期。
  • 胰腺癌(SMR=1.58 [CI 1.18-2.06])、肾及肾盂癌(SMR=1.85 [CI 1.10-2.93])、脑及其他神经系统(SMR=1.62 [CI 0.99-2.51])、骨髓瘤(SMR=2.35 [CI 1.46-3.60])和白血病(SMR=1.62 [CI 1.07-2.36])死亡率升高,且诊断后≥10年关联更强。

关键数值与推荐

  • 低风险分化型甲状腺癌定义为≤4 cm、局限期。
  • 全因(除甲状腺癌外)SMR=0.69 [CI 0.67-0.71]。
  • 所有恶性肿瘤合计(除甲状腺癌外)SMR=0.80 [CI 0.75-0.85]。
  • 心血管疾病SMR=0.64 [CI 0.60-0.69]。
  • 胰腺癌SMR=1.58 [CI 1.18-2.06];肾及肾盂癌SMR=1.85 [CI 1.10-2.93];脑及其他神经系统SMR=1.62 [CI 0.99-2.51];骨髓瘤SMR=2.35 [CI 1.46-3.60];白血病SMR=1.62 [CI 1.07-2.36]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 放射性碘治疗与病因特异性死亡风险无关的结论中,事件数少且给药活度范围可能窄。
  • 需进一步研究以确认和理解某些后续癌症死亡率升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Despite the excellent disease-specific survival associated with low-risk differentiated thyroid cancer (DTC), its diagnosis and management have been linked to patient concerns about cancer recurrence, treatment-related health risks, and mortality. Lack of information regarding long-term health outcomes can perpetuate these concerns. Therefore, we assessed all-cause and cause-specific mortality in a large cohort of individuals diagnosed with low-risk DTC. Methods: From the U.S. Surveillance, Epidemiology, and End Results-12 cancer registry database (1992-2019), we identified 51,854 individuals (81.8% female) diagnosed with first primary DTC at low risk of recurrence (≤4 cm, localized). We estimated cause-specific cumulative mortality by time since diagnosis, accounting for competing risks. Standardized mortality ratios (SMRs) and CIs were used to compare observed mortality rates in DTC patients with expected rates in the matched U.S. general population, overall and by time since DTC diagnosis. We used Cox proportional hazards models to examine associations between radioactive iodine (RAI) treatment and cause-specific mortality. Results: During follow-up (median = 8.8, range 0-28 years), 3467 (6.7%) deaths were recorded. Thyroid cancer accounted for only 4.3% of deaths (n = 148). The most common causes of death were malignancies (other than thyroid cancer) (n = 1031, 29.7%) and cardiovascular disease (CVD; n = 912, 26.3%). The 20-year cumulative mortality rate from thyroid cancer, malignancies (other than thyroid or nonmelanoma skin cancer), and CVD was 0.6%, 4.6%, and 3.9%, respectively. Lower than expected mortality was observed for all causes excluding thyroid cancer (SMR = 0.69 [CI 0.67-0.71]) and most specific causes, including all malignancies combined (other than thyroid cancer; SMR = 0.80 [CI 0.75-0.85]) and CVD (SMR = 0.64 [CI 0.60-0.69]). However, mortality rates were elevated for specific cancers, including pancreas (SMR = 1.58 [CI 1.18-2.06]), kidney and renal pelvis (SMR = 1.85 [CI 1.10-2.93]), and brain and other nervous system (SMR = 1.62 [CI 0.99-2.51]), and myeloma (SMR = 2.35 [CI 1.46-3.60]) and leukemia (SMR = 1.62 [CI 1.07-2.36]); these associations were stronger ≥10 years after diagnosis. RAI was not associated with risk of cause-specific death, but numbers of events were small and the range of administered activities was likely narrow. Conclusions: Overall, our findings provide reassurance regarding low overall and cause-specific mortality rates in individuals with low-risk DTC. Additional research is necessary to confirm and understand the increased mortality from certain subsequent cancers.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tran TV, Schonfeld SJ, Pasqual E, et al. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States. Thyroid. 2024. PMID: 38149602. doi:10.1089/thy.2023.0449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。